Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $236.0 million.

  • Nurix Therapeutics' Cash from Financing Activities rose 1769.74% to $236.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $238.6 million, marking a year-over-year decrease of 5086.3%. This contributed to the annual value of $238.6 million for FY2025, which is 5086.3% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Cash from Financing Activities of $236.0 million as of Q4 2025, which was up 1769.74% from $1.2 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Cash from Financing Activities registered a high of $237.8 million during Q2 2024, and its lowest value of -$135000.0 during Q4 2022.
  • Over the past 5 years, Nurix Therapeutics' median Cash from Financing Activities value was $1.5 million (recorded in 2022), while the average stood at $49.9 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Financing Activities plummeted by 12700.0% in 2022, and later skyrocketed by 286448571.43% in 2024.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Cash from Financing Activities stood at $500000.0 in 2021, then crashed by 127.0% to -$135000.0 in 2022, then soared by 105.19% to $7000.0 in 2023, then skyrocketed by 2864485.71% to $200.5 million in 2024, then increased by 17.7% to $236.0 million in 2025.
  • Its last three reported values are $236.0 million in Q4 2025, $1.2 million for Q3 2025, and $6000.0 during Q2 2025.